Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) generates news centered on its non-invasive, frequency-based neurostimulation devices and their application in mental health and neurological disorders. News coverage for Nexalin often highlights developments related to its proprietary Deep Intracranial Frequency Stimulation (DIFS™) platform, including clinical data, regulatory milestones, and international commercialization activities.
Investors and followers of Nexalin’s news can expect updates on peer-reviewed studies involving the company’s technology in conditions such as Alzheimer’s disease, dementia, attention deficit hyperactivity disorder (ADHD), and gambling disorder with alcohol use disorder comorbidity. Recent announcements have described randomized, sham-controlled trials and case reports that examine changes in cognition, attention, and brain network function using tools like EEG, MEG, and functional MRI, as well as reported safety and tolerability outcomes.
Nexalin’s news flow also includes regulatory and strategic updates, such as Q-Submission interactions with the U.S. Food and Drug Administration for the Gen-2 SYNC™ console in Alzheimer’s disease, acceptance of FDA filings, and discussions of potential De Novo pathways. Internationally, the company reports on regulatory approvals in markets including China, Brazil, Oman, and Israel, along with distribution agreements like its exclusive partnership with Carmi Masha Technologies Ltd. in Israel.
Additional coverage may feature corporate events, investor webinars, conference participation, and Scientific Advisory Board appointments that relate to Nexalin’s focus on mental health, Alzheimer’s disease, and traumatic brain injury research. For users tracking NXLIW and NXL, this news page offers a centralized view of clinical, regulatory, and corporate developments that shape Nexalin’s progress in the neurostimulation and mental health space.
Nexalin (Nasdaq: NXL) announced a planned pivotal, randomized, triple-blinded, sham-controlled 150‑participant trial of HALO™ Clarity for moderate-to-severe insomnia to support a planned de novo submission to the U.S. FDA. The fully decentralized study uses Nexalin’s NeuroCare virtual clinic and EDC, runs four weeks of treatment plus four weeks follow-up, and is conducted with Lindus Health.
The program builds on a prior 120‑participant randomized, double‑blind, placebo‑controlled study published in the Journal of Psychiatric Research and on Nexalin’s Gen‑2 15 mA device regulatory approvals internationally.
Nexalin (Nasdaq: NXL) praised recent bipartisan Congressional actions increasing federal support for deep brain neurostimulation research and said its DIFS™ technology aligns with emerging VA and NIH priorities.
The company noted two appropriations reports signed into law supporting neuromodulation research and an ongoing UC San Diego/San Diego VA study of DIFS™, while H.R. 7091 remains under committee review.
Nexalin (Nasdaq:NXL) launched NeuroCare®, an AI-designed virtual clinic integrated with its new Gen-3 HALO™ headset to deliver home-based Deep Intracranial Frequency Stimulation (DIFS™).
The platform, deployed initially with UC San Diego, supports remote physician monitoring, subscription billing, and clinical trial enrollment for Alzheimer’s, mood disorders, TBI and PTSD.
Nexalin (Nasdaq: NXL) highlighted a growing peer-reviewed neuroimaging literature supporting its Deep Intracranial Frequency Stimulation (DIFS™) as a non-invasive approach that modulates deep brain networks across mood, military, and memory indications.
Key studies include a randomized, double-blind, sham-controlled trial showing objective gamma‑frequency normalization via MEG/EEG and multiple fMRI/PET reports linking network changes to clinical improvement.
Nexalin Technology (Nasdaq: NXL) received a Nasdaq notification dated January 21, 2026 stating it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) after 30 consecutive business days below the $1.00 bid threshold. The company has been granted 180 calendar days, until July 20, 2026, to regain compliance by achieving a closing bid of at least $1.00 for a minimum of 10 consecutive trading days. Shares will continue to trade uninterrupted under ticker NXL. The company said it will monitor the bid price and is considering measures to improve its financial position; it is not considering a reverse stock split at this time.
Nexalin Technology (Nasdaq: NXL) announced a peer‑reviewed, randomized double‑blind sham‑controlled trial published in Molecular Psychiatry showing four weeks of its non‑invasive DIFS™ neurostimulation improved attention and normalized brain activity in adults with ADHD.
In 56 adults, active treatment produced a 10.1‑point average improvement on the Adult ADHD Self‑Report Scale versus 5.5‑points for sham (4.6‑point separation, p < 0.001), plus MEG/EEG evidence of reduced excessive gamma activity and restored network communication. Treatment was well tolerated with no serious adverse events reported.
Nexalin Technology (NASDAQ: NXL) completed a substantive FDA Q-Submission meeting for its Gen-2 SYNC™ neurostimulation console targeting mild-to-moderate Alzheimer’s disease on December 3, 2025. The FDA provided a clear framework for Nexalin’s planned U.S. Pilot Study and discussed a potential De Novo classification pathway.
FDA and Nexalin aligned on pilot and pivotal trial design elements, patient population, dosing paradigm, statistical plan, and primary/secondary endpoints including cognitive tests, PET, blood biomarkers, and functional imaging. Company will use feedback for its U.S. IDE submission.
Nexalin Technology (Nasdaq: NXL) invites investors to a live webinar on December 4, 2025 at 4:15 p.m. ET hosted by RedChip Companies.
CEO Mark White will discuss Nexalin’s proprietary non-invasive Deep Intracranial Frequency Stimulation (DIFS™), recent clinical collaborations including UC San Diego, the Gen-3 HALO™ Clarity headset, and a Virtual Clinic model for scalable at-home treatment. The company says it has secured regulatory approvals internationally while pursuing U.S. expansion and targets the $537 billion mental health market. Management will highlight patented technology, real-time AI-driven patient monitoring, and global footprint growth, followed by a live Q&A. Registration is free at the RedChip webinar page and questions can be pre-submitted to NXL@redchip.com.
Nexalin Technology (Nasdaq: NXL) reported a peer-reviewed case report in The American Journal on Addictions showing promising results using its 15 mA neurostimulation device to treat gambling disorder comorbid with alcohol use disorder.
In a single patient treated at Shanghai Mental Health Center, 20 outpatient sessions over 10 days (15 mA at 77.5 Hz for 40 minutes each) produced complete abstinence from gambling and alcohol, improved cognitive control, and no adverse effects during a three-month follow-up. The study (ClinicalTrials.gov NCT06195995) received ethics approval. The device is approved in China for depression and insomnia. Authors recommend larger controlled trials to confirm findings.
Nexalin Technology (Nasdaq: NXL) announced an exclusive distribution agreement with Carmi Masha Technologies Ltd. to market and sell Nexalin’s Gen-2 SYNC 15 mA non-invasive neurostimulation console in Israel.
The agreement follows regulatory approval by the Israeli Ministry of Health authorizing commercial sale for indications including insomnia, depression, and anxiety. Carmi Masha will handle importation, registration, sales, marketing, clinical education, and distribution to hospitals, clinics, and private centers.
The companies also plan to explore future clinical applications for PTSD, TBI, Alzheimer’s, and dementia as part of ongoing global clinical initiatives.